Peri-operative Chemotherapy With ECX or XP in the Treatment of Advanced Gastric Cancer
The purpose of this study is to evaluate the safety and the effect of perioperative chemotherapy in the treatment of advanced gastric cancer.
Gastric Cancer
DRUG: Peri-operative chemotherapy of ECX|DRUG: Peri-operative chemotherapy of XP
the relapse-free survival time/rate, 3 years
To evaluate the security and the relapse-free survival time/rate(1,2,3 yrs) of perioperative chemotherapy with ECX (epirubicin + cisplatin + capecitabine) and XP (capecitabine + cisplatinï¼‰in advanced gastric cancer